The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Current Standards of Care in Glioblastoma Therapy
Open accessAbstract
Glioblastoma (GBM) is the most common primary malignant brain tumor in adults. Regardless of ideal multidisciplinary treatment, including maximal surgical resection, followed by radiotherapy plus concomitant and maintenance temozolomide (TMZ), almost all patients experience tumor progression with nearly universal mortality and a median survival of less than 15 months. The addition of bevacizumab to standard treatment with TMZ revealed no increase in overall survival (OS) but improved progression-free survival (PFS). In newly diagnosed GBM, methylation of the O6-methylguanine-DNA methyltransferase (MGMT) promoter has been shown to predict response to alkylating agents, as well as prognosis. Therefore, MGMT promoter status may have a crucial role in the choice of single modality treatment in fragile elderly population. No standard of care is established in recurrent or progressive GBM. Treatment alternatives may include supportive care, surgery, re-irradiation, systemic therapies, and combined modality therapy. Despite numerous clinical trials, the identification of effective therapies is complex because of the lack of appropriate control arms, selection bias, small sample sizes, and disease heterogeneity. Tumor-treating fields plus TMZ represent a major advance in the field of GBM therapy, and should be considered for patients with newly diagnosed GBM with no contraindications. As a disease with such a poor prognosis, treatment of GBM should go beyond improving survival and aim at preserving and even improving the quality of life of both the patient and the caregiver.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer
Temel, J. S., Greer, J. A., Muzikansky, A., Gallagher, E. R., Admane, S., Jackson, V. A., Dahlin, C. M., Blinderman, C. D., Jacobsen, J., Pirl, W. F., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000678 · Cited by 7,482
Stummer, W., Pichlmeier, U., Meinel, T., Wiestler, O. D., Zanella, F., & Reulen, H.-J. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70665-9 · Cited by 3,423 · cited 1×
“(25, 26), and also increases PFS (8.6 vs. 4.8 months) and the 6-month PFS (PFS6) (46% vs. 28”
InfluentialA Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Gilbert, M. R., Dignam, J. J., Armstrong, T. S., Wefel, J. S., Blumenthal, D. T., Vogelbaum, M. A., Colman, H., Chakravarti, A., Pugh, S., Won, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308573 · Cited by 2,834 · cited 4×
“That finding caused considerable debate regarding whether the combination is cost-effective in first-line treatment (4, 5).”
BackgroundMethodInfluentialDose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
Gilbert, M. R., Wang, M., Aldape, K. D., Stupp, R., Hegi, M. E., Jaeckle, K. A., Armstrong, T. S., Wefel, J. S., Won, M., Blumenthal, D. T., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.6968 · Cited by 1,063
Stupp, R., Hegi, M. E., Gorlia, T., Erridge, S. C., Perry, J., Hong, Y.-K., Aldape, K. D., Lhermitte, B., Pietsch, T., Grujicic, D., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70379-1 · Cited by 1,052 · cited 2×
“Data from a large pooled analysis of four clinical trials for nGBM indicates that extended treatment with TMZ beyond six cycles is not associated with improved OS, but prolongs PFS (2, 3, 46–48).”
BackgroundRadiation activates HIF-1 to regulate vascular radiosensitivity in tumors
Moeller, B. J., Cao, Y., Li, C. Y., & Dewhirst, M. W. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00115-1 · Cited by 996
Yung, W. K. A., Albright, R. E., Olson, J., Fredericks, R., Fink, K., Prados, M. D., Brada, M., Spence, A., Hohl, R. J., Shapiro, W., et al. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1316 · Cited by 929 · cited 4×
“In both trials leading to the approval of TMZ, the sdTMZ schedule was used (126, 127).”
BackgroundMethodInfluentialOutcomes and Prognostic Factors in Recurrent Glioma Patients Enrolled Onto Phase II Clinical Trials
Wong, E. T., Hess, K. R., Gleason, M. J., Jaeckle, K. A., Kyritsis, A. P., Prados, M. D., Levin, V. A., & Yung, W. K. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2572 · Cited by 902 · cited 1×
“Previous reports on salvage therapy for rGBM showed inferior efficacy results, with RR of 5–10%, PFS6 rate of 9–25%, and median OS of 5 to 6 months (108, 202, 203).”
BackgroundPleiotropic effects of HIF-1 blockade on tumor radiosensitivity
Moeller, B. J., Dreher, M. R., Rabbani, Z. N., Schroeder, T., Cao, Y., Li, C. Y., & Dewhirst, M. W. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.06.016 · Cited by 374
Cited by
Hersh, A. M., Alomari, S., & Tyler, B. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084153 · Cited by 478
Current FDA-Approved Therapies for High-Grade Malignant Gliomas
Fisher, J. P., & Adamson, D. C. (2021) · Biomedicines · doi:10.3390/biomedicines9030324 · Cited by 316
Pathological and Molecular Features of Glioblastoma and Its Peritumoral Tissue
D’Alessio, A., Proietti, G., Sica, G., & Scicchitano, B. M. (2019) · Cancers · doi:10.3390/cancers11040469 · Cited by 275
Immunotherapy Resistance in Glioblastoma
Wang, E. J., Chen, J.-S., Jain, S., Morshed, R. A., Haddad, A. F., Gill, S., Beniwal, A. S., & Aghi, M. K. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.750675 · Cited by 34
Caregiver burden by treatment and clinical characteristics of patients with glioblastoma
Au, T. H., Willis, C., Reblin, M., Peters, K. B., Nghiemphu, P. L., Taylor, J. W., Colman, H., Cohen, A. L., Ormond, D. R., Chakravarti, A., et al. (2022) · Supportive Care in Cancer · doi:10.1007/s00520-021-06514-0 · Cited by 34
Metadata
- Authors
- Department of Medical Oncology, C. H. D. S. J., FERNANDES, C., COSTA, A., Department of Medical Oncology, C. H. D. S. J., OSÓRIO, L., Department of Radiotherapy, C. H. D. S. J., LAGO, R. C., Department of Radiotherapy, C. H. D. S. J., LINHARES, P., Department of Neurosurgery, C. H. D. S. J., Faculty of Medicine of the University of Porto, P., CARVALHO, B., Department of Neurosurgery, C. H. D. S. J., Faculty of Medicine of the University of Porto, P., CAEIRO, C., & Department of Medical Oncology, C. H. D. S. J.
- Venue
- Glioblastoma
- Publisher
- Codon Publications
- Published
- 2017-09-22
- Pages
- 197-241
- OpenAlex
- W2756498897
- Cited by
- 234
- References
- 12
- FWCI
- 34.99
- Type
- book chapter
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Current Standards of Care in Glioblastoma Therapy. https://app.cochat.ai/papers/10.15586/codon.glioblastoma.2017.ch11
- The paper
- Department of Medical Oncology, C. H. D. S. J., FERNANDES, C., COSTA, A., Department of Medical Oncology, C. H. D. S. J., OSÓRIO, L., Department of Radiotherapy, C. H. D. S. J., LAGO, R. C., Department of Radiotherapy, C. H. D. S. J., LINHARES, P., Department of Neurosurgery, C. H. D. S. J., Faculty of Medicine of the University of Porto, P., CARVALHO, B., Department of Neurosurgery, C. H. D. S. J., Faculty of Medicine of the University of Porto, P., CAEIRO, C., & Department of Medical Oncology, C. H. D. S. J. (2017). Current Standards of Care in Glioblastoma Therapy. Glioblastoma. https://doi.org/10.15586/codon.glioblastoma.2017.ch11
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.